Weekly Carfilzomib Safe and Effective in Relapsed or Refractory Multiple Myeloma
August 15th 2014Administering carfilzomib once weekly in combination with dexamethasone is safe, with few ≥3 adverse events, and has significant antitumor activity in the treatment of patients with relapsed or refractory multiple myeloma.
Ceritinib Demonstrates Durable Response in ALK-Positive Lung Cancer
August 7th 2014The second-generation oral ALK inhibitor ceritinib (Zykadia; LDK378) demonstrated rapid and durable responses in patients with ALK-positive, metastatic, non–small cell lung cancer (NSCLC)-regardless of whether they had been previously treated with crizotinib-achieving overall response rates of 60% or more in each subgroup of patients who had received zero to three prior therapies for their advanced lung cancer.
Crizotinib Established as First-Line Therapy for ALK-Positive NSCLC
August 4th 2014As a first-line treatment, crizotinib (Xalkori) improved progression-free survival (PFS) and objective response rate (ORR) compared with standard chemotherapy in patients with advanced ALK-positive non–small cell lung cancer (NSCLC).
Anti-PD-L1 Antibody MEDI4736 Shows Clinical Activity in NSCLC and Is Well Tolerated
July 30th 2014The anti-PD-L1 antibody MEDI4736 has early and durable activity in patients with non–small cell lung cancer (NSCLC) of both squamous and nonsquamous histology, with higher objective response rates occurring in PD-L1–positive patients, according to results of an ongoing phase I study.
Immunotherapy Advances in Melanoma
July 28th 2014Melanoma care has fortunately undergone a whirlwind of changes over the past several years. Novel immunotherapies are perhaps the most exciting recent development in cancer care because patients can enjoy long-term benefit from these treatments, meaning that they are possibly "cured."
Cabozantinib Reduces Tumor Growth After Erlotinib Failure in NSCLC
July 22nd 2014Cabozantinib added to erlotinib has antitumor activity in heavily pretreated patients with EGFR-positive non–small cell lung cancer (NSCLC) whose disease progressed on erlotinib alone, according to the results of a phase II trial presented at the 2014 ASCO Annual Meeting.